Project Grant HT94252510385
Award Date
6/15/25
Completion Date
6/14/28
Dollars Obligated
$989K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10022, USA
Similar Awards
This $312,610 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Weill Medical College of Cornell University focused on the "Role of Functional Factors in AR Reprogramming and Progression of Prostate Cancer." The 2-year grant, running from September 2024 to September 2026, will fund cutting-edge investigations into the cellular mechanisms driving...
This $1,518,817 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by Weill Medical College of Cornell University to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The research aims to advance understanding of the cellular processes underlying therapy resistance in aggressive prostate cancer, with the goal of developing...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,356,000.00 to the Weill Medical College of Cornell University to conduct research on the "RESTORATION OF CLEAR CELL RENAL CELL CARCINOMA TUMORIGENICITY BY CELL REPROGRAMMING." The 4-year award, with a performance period from November 1, 2024 to October 31, 2028, supports advanced biomedical research initiatives focused on...
This federal Project Grant award for $847,501.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Weill Medical College of Cornell University on the role of BCL-XL in breast cancer metastasis and therapy. The project aims to advance the understanding of cellular mechanisms underlying breast cancer progression and investigate potential therapeutic interventions. As a leading academic medical...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $808,141.00 to Weill Medical College of Cornell University to conduct research targeting inflammatory pathways in breast cancer brain metastases. The purpose is to develop treatments for edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. The project will be performed from February 1, 2025 through January 31, 2027. As...
This $677,998 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by the Weill Medical College of Cornell University to target extrachromosomal DNA (ecDNA) to reverse therapy resistance in urothelial cancer. The 3-year award, running from September 1, 2024 to August 31, 2027, will enable the institution to conduct advanced biomedical research focusing on innovative approaches to...
This federal Project Grant award, valued at $2,542,500.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by Weill Medical College of Cornell University to investigate therapeutic targeting of the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse, as well as preclinical models of lung metastases. The performance period for this grant is from May 15,...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $762,750.00 to Weill Medical College of Cornell University to conduct "NUTRITION-BASED PROGRAMMING OF DENDRITIC CELLS FOR OVARIAN CANCER IMMUNOTHERAPY" research. The award period runs from May 1, 2025 to April 30, 2028. This grant supports advanced biomedical research initiatives focused on transforming healthcare for...
The Department of the Army Medical Command awarded a $762,750 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research on perk-driven stress responses that regulate dendritic cell function in ovarian cancer. Through June 2024, Weill Medical College will investigate how stress responses impact immune cell activity and how this relationship influences ovarian cancer progression....